	US 12,285,421 B2
	Uses of a 5-HT4 receptor agonist
Ramakrishna Nirogi, Hyderabad (IN); Abdul Rasheed Mohammed, Hyderabad (IN); Anil Karbhari Shinde, Hyderabad (IN); Venkata Ramalingayya Grandhi, Hyderabad (IN); Pradeep Jayarajan, Hyderabad (IN); Vijay Benade, Hyderabad (IN); Gopinadh Bhyrapuneni, Hyderabad (IN); and Venkateswarlu Jasti, Hyderabad (IN)
Assigned to SUVEN LIFE SCIENCES LIMITED, Hyderabad-Telangana (IN)
Appl. No. 17/285,815
Filed by SUVEN LIFE SCIENCES LIMITED, Hyderabad-Telangana (IN)
PCT Filed Oct. 17, 2019, PCT No. PCT/IB2019/058853 § 371(c)(1), (2) Date Apr. 15, 2021, PCT Pub. No. WO2020/079630, PCT Pub. Date Apr. 23, 2020.
Claims priority of application No. 201841039516 (IN), filed on Oct. 18, 2018.
Prior Publication US 2021/0386727 A1, Dec. 16, 2021
Int. Cl. A61K 31/454 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/454 (2013.01) [A61P 25/24 (2018.01); A61P 25/28 (2018.01)]

4 Claims

1. A method of treating depression comprising the step of administering to a patient in need thereof, a therapeutically effective amount of a 5-HT₄receptor agonist and a selective serotonin reuptake inhibitor, wherein the 5-HT₄receptor agonist is a compound, Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole or a pharmaceutically acceptable salt thereof; and wherein the selective serotonin reuptake inhibitor is selected from the group consisting of paroxetine, citalopram, escitalopram, fluoxetine, sertraline, dapoxetine and vilazodone, or a pharmaceutically acceptable salt thereof.